Evidence map›Paper›PMID 26399469›Full record

ArticleCirculation research2015

Interferon-γ-mediated allograft rejection exacerbates cardiovascular disease of hyperlipidemic murine transplant recipients.

Jing Zhou, Lingfeng Qin, Tai Yi, Rahmat Ali, Qingle Li, Yang Jiao, Guangxin Li, Zuzana Tobiasova, Yan Huang, Jiasheng Zhang and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Cytokines associated with immune response in atherosclerosis.American journal of translational research · 2022
    Review
  8. Article
  9. The role of interferon-γ in cardiovascular disease: an update.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020
    Review
  10. IL-27 RαJournal of cellular and molecular medicine · 2020
    Article
  11. Innate immune mechanisms in transplant allograft vasculopathy.Current opinion in organ transplantation · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Jing ZhouFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.). george.tellides@yale.edu zhou.jing@yale.edu.
Lingfeng QinFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Tai YiFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Rahmat AliFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Qingle LiFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Yang JiaoFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Guangxin LiFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Zuzana TobiasovaFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Yan HuangFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Jiasheng ZhangFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
James J YunFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Mehran M SadeghiFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Frank J GiordanoFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
Jordan S PoberFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.).
George TellidesFrom the Departments of Surgery (J.Z., L.Q., R.A., Q.L., Y.J., G.L., J.J.Y., G.T.) and Immunobiology (T.Y., Z.T., J.S.P.) and Medicine (Y.H., J.Z., M.M.S., F.J.G.) and the Interdepartmental Program in Vascular Biology and Therapeutics (J.J.Y., M.M.S., F.J.G., J.S.P., G.T.), Yale University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Healthcare System, West Haven (J.J.Y., M.M.S., F.J.G., G.T.); Research Institute, Nationwide Children's Hospital, Columbus, OH (T.Y.); and Department of Vascular Surgery, Peking University People's Hospital, Beijing, P.R. China (Q.L., Y.J.). george.tellides@yale.edu zhou.jing@yale.edu.
Nationwide Children's Hospital · USVA Connecticut Healthcare System · US

Funding

Regulating Anti-Endothelial T Cell Responses in Graft ArteriosclerosisR01HL109455 · NHLBI · YALE UNIVERSITY · PI BOTHWELL, ALFRED LM, POBER, JORDAN S · 2011 to 2014
$2.5M
NHLBI NIH HHS R01 HL109455NHLBI NIH HHS R01-HL109455
6 · The paper itself

Abstract

rationaleTransplantation, the most effective therapy for end-stage organ failure, is markedly limited by early-onset cardiovascular disease (CVD) and premature death of the host. The mechanistic basis of this increased CVD is not fully explained by known risk factors.

objectiveTo investigate the role of alloimmune responses in promoting CVD of organ transplant recipients. METHODS AND

resultsWe established an animal model of graft-exacerbated host CVD by combining murine models of atherosclerosis (apolipoprotein E-deficient recipients on standard diet) and of intra-abdominal graft rejection (heterotopic cardiac transplantation without immunosuppression). CVD was absent in normolipidemic hosts receiving allogeneic grafts and varied in severity among hyperlipidemic grafted hosts according to recipient-donor genetic disparities, most strikingly across an isolated major histocompatibility complex class II antigen barrier. Host disease manifested as increased atherosclerosis of the aorta that also involved the native coronary arteries and new findings of decreased cardiac contractility, ventricular dilatation, and diminished aortic compliance. Exacerbated CVD was accompanied by greater levels of circulating cytokines, especially interferon-γ and other Th1-type cytokines, and showed both systemic and intralesional activation of leukocytes, particularly T-helper cells. Serological neutralization of interferon-γ after allotransplantation prevented graft-related atherosclerosis, cardiomyopathy, and aortic stiffening in the host.

conclusionsOur study reveals that sustained activation of the immune system because of chronic allorecognition exacerbates the atherogenic diathesis of hyperlipidemia and results in de novo cardiovascular dysfunction in organ transplant recipients.

Indexed as

AllograftsAnimalsAortic DiseasesApolipoproteins EAtherosclerosisCardiomyopathiesCardiovascular DiseasesDisease Models, AnimalFemaleGraft RejectionHeart TransplantationHemodynamicsHistocompatibility Antigens Class IIHyperlipidemiasInflammation MediatorsInterferon-gammaApolipoproteins EHistocompatibility Antigens Class IIInflammation MediatorsInterferon-gammaatherosclerosiscardiovascular diseaseinterferonslymphocytestransplantation

Identifiers

PMID26399469
PMCPMC4636943
OpenAlexW2266384908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.